Feature | May 14, 2014

Leadless Pacemaker Showing Promising Results After One Year

Follow-up results for Nanostim presented in late-breaking clinical trial presentation at Heart Rhythm 2014

May 14, 2014 — Vivek Reddy, M.D., director of arrhythmia services for The Mount Sinai Hospital, reported promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Reddy presented the one-year LEADLESS study data findings during a late-breaking clinical trial presentation on Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim leadless pacemaker at hospitals in Prague and in Amsterdam. The findings, which assessed device performance and patient outcomes through 12 months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace or communicate with the pacemaker.

"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology, and our results show the leadless pacemaker is comparable to traditional pacemakers," says Reddy, who is the study's co-investigator and chairman of its steering committee. "Our latest findings further support the promising performance and safety of this minimally invasive, nonsurgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials."

In February, Reddy was the first to implant the leadless pacemaker in the United States. The multicenter clinical trial LEADLESS II aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the United States and Canada.

The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than 10 percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms, and if the heartbeat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.

In comparison to a conventional pacemaker, the leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.

The LEADLESS study was funded by St. Jude Medical, manufacturer of the Nanostim pacemaker. Reddy receives financial compensation as a consultant and advisory board member for St. Jude Medical. In addition, in 2013 he received one-time financial compensation from St. Jude Medical in the form of an option buyout relating to St. Jude Medical's acquisition of Nanostim.

For more information: www.mountsinai.org, www.sjm.com

Related Content

Image courtesy of Boston Scientific

Feature | Business| February 10, 2016 | Dave Fornell
After five years of almost constant lobbying efforts and numerous attempts by the U.S.
cardiomyocytes, electrical stimulation, human stem cells, Columbia Engineering

Electrically conditioned human cardiomyocytes. Striated ultrastructure containing troponin ( stained in green) forms around cell nuclei (stained in blue.) Image courtesy of Benjamin Lee, Columbia Engineering

News | Stem Cell Therapies| February 09, 2016
Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
caffeine consumption, extra heartbeats, UCSF study, UC San Francisco, Journal of the American Heart Association
News | EP Lab| February 04, 2016
Contrary to current clinical belief, regular caffeine consumption does not lead to extra heartbeats, which, while...
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
Biotronik, CE approval, Ilivia ICDs and CRT-Ds, ProMRI, MRI AutoDetect
News | Implantable Cardioverter Defibrillators (ICD)| February 03, 2016
Biotronik announced CE approval for its new Ilivia implantable cardioverter defibrillators (ICDs) and cardiac...
Abbott, Kalila Medical, acquisition, electrophysiology offerings

Vado Steerable Introducer Sheath image courtesy of Kalila Medical

News | Ablation Systems| February 02, 2016
Abbott announced that it has acquired private medical device company Kalila Medical Inc. Kalila Medical is a developer...
Allegheny General Hospital, MRI, patients with implantable cardiac devices, safety and effectiveness
News | EP Lab| February 01, 2016
The findings of a major study led by cardiovascular imaging specialists at Allegheny General Hospital (AGH) suggest...
News | EP Lab| January 29, 2016
Diseased hearts may be thrown out of rhythm by structural differences, now visible for the first time, in protein...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
Overlay Init